GlaxoSmithKline Pharmaceuticals Salute del bilancio
Salute finanziaria criteri di controllo 6/6
GlaxoSmithKline Pharmaceuticals ha un patrimonio netto totale di ₹16.7B e un debito totale di ₹0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente ₹37.5B e ₹20.7B. L'EBIT di GlaxoSmithKline Pharmaceuticals è ₹9.6B rendendo il suo rapporto di copertura degli interessi -13.5. Ha liquidità e investimenti a breve termine pari a ₹21.1B.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
₹0
Debito
| Indice di copertura degli interessi | -13.5x |
| Contanti | ₹21.11b |
| Patrimonio netto | ₹16.73b |
| Totale passività | ₹20.73b |
| Totale attività | ₹37.46b |
Aggiornamenti recenti sulla salute finanziaria
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02Recent updates
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 01We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Analisi della posizione finanziaria
Passività a breve termine: Le attività a breve termine ( ₹30.1B ) di GLAXO superano le sue passività a breve termine ( ₹18.1B ).
Passività a lungo termine: Le attività a breve termine di GLAXO ( ₹30.1B ) superano le sue passività a lungo termine ( ₹2.6B ).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: GLAXO è esente da debiti.
Riduzione del debito: GLAXO non ha debiti rispetto a 5 anni fa, quando il suo rapporto debito/patrimonio netto era 0.01%.
Copertura del debito: GLAXO non ha debiti, pertanto non deve essere coperto dal flusso di cassa operativo.
Copertura degli interessi: GLAXO non ha debiti, pertanto la copertura dei pagamenti degli interessi non è un problema.